CLAIMS:

July A

5

- A pharmaceutical composition comprising a mycophenolate salt, the composition being adapted to release mycophenolate in the upper part of the intestinal tract.
- 2. A pharmaceutical composition comprising an enteric coated pharmaceutically acceptable mycophenolate salt.
- 3. Use of an enteric coated pharmaceutically acceptable mycophenolate salt or composition of claim 1 or 2 in the preparation of a medicament for immunosuppression, particularly for prevention or treatment of native or transgenic organ, tissue or cellular allograft or xenograft transplant rejection; for the treatment or prevention of immune-mediated and/or inflammatory diseases; optionally with the simultaneous or separate administration of another immunosuppressant.
- 4. A method of immunosuppressing a subject which comprises administering a therapeutically effective amount of enteric coated pharmaceutically acceptable mycophenolate or a composition of claim 1 or 2 to a subject in need of such immunosuppression, optionally with the simultaneous or separate administration of another immunosuppressant
- 5. A composition containing an enteric coated pharmaceutically acceptable mycophenolate salt or a composition of claim 1 or 2 and another immunosuppressant for simultaneous, sequential or separate administration.
- 6. A composition, use or method according to any preceding claim wherein the sodium salt is the mono-sodium salt.
 - 7. A composition, use or method according to any preceding claim wherein another immunosuppressant is present, e.g. ciclosporin.

MB

10

15